Primary: To estimate efficacy of SR29142 to the pediatric patients with newly diagnosed
hematological malignancies at high risk for Tumor Lysis Syndrome, by evaluation of plasma
uric acid concentration.
Secondary: To investigate the safety in this population and anti-SR29142 antibodies, anti-SCP
antibodies, and pharmacokinetic parameters.